Cover Image
市場調查報告書

類鐸受體8:開發中產品分析

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 366668
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
類鐸受體8:開發中產品分析 Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018
出版日期: 2018年05月16日 內容資訊: 英文 75 Pages
簡介

本報告提供以類鐸受體8為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

類鐸受體8 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • 3M Drug Delivery Systems
  • Foamix Pharmaceuticals Ltd.
  • Folia Biotech Inc.
  • Galderma S.A.
  • Idera Pharmaceuticals, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Resolve Therapeutics, LLC
  • VentiRx Pharmaceuticals, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1450TDB

Summary:

According to the recently published report 'Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018'; Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.

The report 'Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018' outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 5, 6, 1 and 4 respectively.

Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Musculoskeletal Disorders, Dermatology, Gastrointestinal and Respiratory which include indications Cutaneous T-Cell Lymphoma, Solid Tumor, Colorectal Cancer, Melanoma, Renal Cell Carcinoma, Systemic Lupus Erythematosus, Actinic (Solar) Keratosis, Allergic Rhinitis, Arthritis, Autoimmune Disorders, Breast Cancer, Crohn's Disease (Regional Enteritis), Dermatomyositis, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hepatitis B, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Sarcomas, Sicca Syndrome (Sjogren), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ulcerative Colitis and Warts.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)
  • The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Toll Like Receptor 8 (CD288 or TLR8) - Overview
    • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • BioNTech AG
    • Celgene Corp
    • Dynavax Technologies Corp
    • Eisai Co Ltd
    • Galderma SA
    • Gilead Sciences Inc
    • Idera Pharmaceuticals Inc
    • Janus Biotherapeutics Inc
    • MedImmune LLC
    • Nektar Therapeutics
    • Pfizer Inc
    • Vivelix Pharmaceuticals Ltd
  • Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles
    • 854-A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bazlitoran sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CUCPT-8m - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DN-1508052 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • durvalumab + MEDI-9197 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DV-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-6742 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-9688 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMO-9200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JB-6121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-9197 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • motolimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NKTR-262 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • resiquimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RSLV-132 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SC-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTX-1463 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products
  • Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products
  • Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 15, 2018: Nektar Therapeutics Presents New Preclinical Data on NKTR-262 at the American Association for Cancer Research (AACR) Annual Meeting 2018
      • Apr 11, 2018: Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors
      • Nov 07, 2017: Nektar to Present New On Drug Candidate NKTR-262 At 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting
      • Aug 22, 2016: Resolve Therapeutics Announces Publication Of Clinical Data Demonstrating The Role Of Circulating RNA In Systemic Lupus Erythematosus
      • Jul 12, 2016: Mayo Clinic researchers identify potential immunotherapy drug combination
      • May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference
      • Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study
      • Dec 05, 2015: Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom's Macroglobulinemia
      • Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis
      • Nov 05, 2015: Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstrom's Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting
      • May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors
      • Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer
      • Apr 01, 2015: Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma
      • Dec 30, 2014: Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia
      • Dec 08, 2014: Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by AstraZeneca Plc, H1 2018
  • Pipeline by BioNTech AG, H1 2018
  • Pipeline by Celgene Corp, H1 2018
  • Pipeline by Dynavax Technologies Corp, H1 2018
  • Pipeline by Eisai Co Ltd, H1 2018
  • Pipeline by Galderma SA, H1 2018
  • Pipeline by Gilead Sciences Inc, H1 2018
  • Pipeline by Idera Pharmaceuticals Inc, H1 2018
  • Pipeline by Janus Biotherapeutics Inc, H1 2018
  • Pipeline by MedImmune LLC, H1 2018
  • Pipeline by Nektar Therapeutics, H1 2018
  • Pipeline by Pfizer Inc, H1 2018
  • Pipeline by Vivelix Pharmaceuticals Ltd, H1 2018
  • Dormant Projects, H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top